Compare SGI & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGI | VTRS |
|---|---|---|
| Founded | 1846 | 1961 |
| Country | United States | United States |
| Employees | 19000 | 30000 |
| Industry | Home Furnishings | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.3B | 18.7B |
| IPO Year | N/A | 2019 |
| Metric | SGI | VTRS |
|---|---|---|
| Price | $74.15 | $16.19 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 4 |
| Target Price | ★ $97.88 | $13.50 |
| AVG Volume (30 Days) | 2.5M | ★ 9.6M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | 0.90% | ★ 3.21% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.15 |
| Revenue | N/A | ★ $14,299,900,000.00 |
| Revenue This Year | $7.30 | $4.41 |
| Revenue Next Year | $4.99 | $1.96 |
| P/E Ratio | ★ $48.98 | $108.93 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $60.39 | $8.63 |
| 52 Week High | $98.56 | $17.53 |
| Indicator | SGI | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 50.38 | 50.20 |
| Support Level | $72.02 | $16.02 |
| Resistance Level | $79.25 | $16.54 |
| Average True Range (ATR) | 2.41 | 0.43 |
| MACD | -0.40 | 0.02 |
| Stochastic Oscillator | 34.24 | 53.94 |
Somnigroup International Inc is a bedding company, dedicated to improving people's lives through good sleep. With superior capabilities in design, manufacturing, distribution and retail, It delivers breakthrough sleep solutions and serves the evolving needs of consumers in more than 100 countries world-wide through its fully-owned businesses Mattress Firm, Tempur Sealy North America and Tempur Sealy International. The company's portfolio includes the brand such as Tempur-Pedic, Sealy and Stearns & Foster, and its Multinational omnichannel platform enables the company to meet consumers wherever shop, offering a personal connection and innovation to provide a retail experience and tailored solutions.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.